The Importance of Prompt Diagnosis and Referral in Moderate to Severe RA

The importance of recognizing RA sooner

As a primary care physician, you may be the first physician a patient sees when he or she experiences symptoms of rheumatoid arthritis (RA). Studies have shown that over half of patients suffer from joint damage by the time they are diagnosed with RA, so it is crucial that these patients are referred to a rheumatologist as soon as possible, to help inhibit further progression.1-5

Serial x-rays show structural damage of RA over time6

Serial x-rays show structural damage of RA over time
Changes can be seen in joints of the hands, beginning with (A) the swelling of the soft tissue, but with intact underlying cortex and no erosions.
This is followed by (B) thinning of the radial side of the cortex with minimal disturbance of underlying trabeculae and minimal joint space narrowing.
A marginal erosion (C) appears on the radial aspect of the metacarpal head. There is loss of bone substance and joint space narrowing.
©2009 American College of Rheumatology. Images used with permission.

The earlier that RA is diagnosed, the sooner treatment can be initiated that can help inhibit progression of joint damage. If a patient appears to be experiencing symptoms of RA, refer them to a rheumatologist as soon as possible.5

Symptoms to watch for

RA symptoms may include7-9:

  • Morning joint stiffness
  • Joint pain
  • Joint swelling, commonly observed in the hands
  • Weakness
  • Fatigue

Help your patients prepare for their appointment with a rheumatologist

This downloadable conversation guide is designed to help patients prepare for their appointment with a rheumatology specialist. Questions include, "What are my treatment options for RA?" and "When can I expect results?"

Download Conversation Guide for Patients and Rheumatologists

RAconversations is a video series created to demonstrate common discussions that a patient may have with a rheumatology specialist, from questions about the condition to information about taking ENBREL for RA.

View RAconversations

Browse additional patient support materials

 
Supportive data
Moderate to Severe Rheumatoid Arthritis

In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.

Psoriatic Arthritis

In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Important Safety Considerations

Lean on
ENBREL Support for personalized patient assistance

Here's how we can help

The experience of ENBREL

Evaluated in RA clinical studies over the past 20 years*

See our timeline history
*Initial clinical research in RA patients began in 1993.
 
 
Close
You are leaving Enbrel.com/RheumPro
Please know that Amgen does not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy  Terms of Use
This site is intended for US Audiences only.
©2013 Amgen, Inc., Thousand Oaks, CA 91320
Close
E-mail this page to a colleague
Please correct the fields marked in red
Send
This content is for US health care professionals only. Amgen will not use your e-mail address or your colleague's e-mail address for any other purpose. To learn more about our use of your information and your rights, please consult our Privacy Policy.
Close

Send another e-mail
Return to enbrel.com/RheumPro

Close
We're sorry.

This content is not available at this time.

Close
Notice

The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

If you are a resident of a country other than the United States, please visit the Amgen website to find information about our offices around the globe.
Close
Phil Mickelson: A PsA patient's perspective
Close
Disease activity vs. structural progression in RA
Close
Treating Moderately Active RA
Close
Rapid, Sustained Efficacy of ENBREL
Close
Improving Outcomes in Psoriatic Arthritis
Close
A look back at 15 years